Home
Resources
Publications
Interleukin-8 as a Therapeutic Target for Chronic Low Back Pain: Upregulation in Human Cerebrospinal Fluid and Pre-Clinical Validation With Chronic Reparixin in the SPARC-null Mouse Model

Interleukin-8 as a Therapeutic Target for Chronic Low Back Pain: Upregulation in Human Cerebrospinal Fluid and Pre-Clinical Validation With Chronic Reparixin in the SPARC-null Mouse Model

Emerson Krock, Magali Millecamps, Kathleen M Anderson, Akanksha Srivastava, Troy E Reihsen, Pawan Hari, Yue Ran Sun, Seon Ho Jang, George L Wilcox, Kumar G Belani, David S Beebe, Jean Ouellet, Manuel R Pinto, etc.

EBioMedicine. 2019 May;43:487-500.

PMID: 31047862

Abstract:

Background:
Low back pain (LBP) is the leading global cause of disability and is associated with intervertebral disc degeneration (DD) in some individuals. However, many adults have DD without LBP. Understanding why DD is painful in some and not others may unmask novel therapies for chronic LBP. The objectives of this study were to a) identify factors in human cerebrospinal fluid (CSF) associated with chronic LBP and b) examine their therapeutic utility in a proof-of-concept pre-clinical study.
Methods:
Pain-free human subjects without DD, pain-free human subjects with DD, and patients with chronic LBP linked to DD were recruited and lumbar MRIs, pain and disability levels were obtained. CSF was collected and analyzed by multiplex cytokine assay. Interleukin-8 (IL-8) expression was confirmed by ELISA in CSF and in intervertebral discs. The SPARC-null mouse model of progressive, age-dependent DD and chronic LBP was used for pre-clinical validation. Male SPARC-null and control mice received systemic Reparixin, a CXCR1/2 (receptors for IL-8 and murine analogues) inhibitor, for 8 weeks. Behavioral signs of axial discomfort and radiating pain were assessed. Following completion of the study, discs were excised and cultured, and conditioned media was evaluated with a protein array.
Findings:
IL-8 was elevated in CSF of chronic LBP patients with DD compared to pain-free subjects with or without DD. Chronic inhibition with reparixin alleviated low back pain behaviors and attenuated disc inflammation in SPARC-null mice.
Interpretation:
These studies suggest that the IL-8 signaling pathway is a viable therapy for chronic LBP. FUND: Supported by NIH, MMF, CIHR and FRQS.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
IAR42414839	LBP from mouse			Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: